EUCTR2013-002584-25-GB进行中（未招募）1 期
altrexone Enhanced Addiction Treatment (NEAT): A randomised controlled trial of the clinical and cost-effectiveness of extended-release naltrexone and oral naltrexone. - Naltrexone Enhanced Addiction Treatment (NEAT)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion criteria for the study are intended to be as close to clinical practice as possible. Each participant in the trial must meet all of the following criteria:
- •1. Is 18 years of age or older.
- •2. Can demonstrate a verbal understanding of the study patient information material, is able to provide written consent, and can understand and confirm willingness to comply with the protocol.
- •3. Has a diagnosis of opioid use disorder based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5: past 12 months),) conducted at baseline.
- •4. Is completing or has recently completed an inpatient or outpatient treatment for opioid detoxification, or has been completely and continuously abstinent from all opioids for at least seven days.
- •5. Has no tolerance to opioids, as verified by a negative urine toxicology screening test prior to randomisation (using an instant result immunoassay device).
- •6. Passes a naloxone challenge test (to confirm zero opioid tolerance by demonstrating no clinical sign or subjective report of opioid withdrawal before randomisation and prior to implant procedure) NB: Individuals failing screening will be allowed to enter screening as clinically indicated.
- •7. Is voluntarily seeking opioid antagonist treatment for opioid use disorder.
- •8. Lives in stable/secure accommodation in the community.
- •9. Has a personal (mobile/cellular) phone, and is able to nominate at least one locator individual (e.g. a family member, friend or recovery mentor) with a verifiable address and a telephone number to assist with the arrangement of follow-up appointments as required.
- •10. If female, is not pregnant or breast feeding and agrees to use a birth control method (either oral hormonal contraceptives, barrier [condom or diaphragm], or Nexplanon implant) for the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •Otherwise eligible individuals who meet any of the following criteria will be excluded from the study:
- •1. Clinically significant medical condition or observed abnormalities on physical examination or laboratory investigation, including but not limited to:
- •? Uncontrolled hypertension;
- •? Significant heart disease (including angina and myocardial infarction in past 12 months);
- •? Any ECG/cardiovascular abnormality which, in the investigator’s judgment, is clinically significant.
- •2. Severe alcohol dependence and/or alcohol withdrawal (by clinical assessment).
- •3. Opioid withdrawal syndrome, current.
- •4. Positive test for presence of opioids in urine (i.e. indicating current opioid use) prior to randomisation (using an instant result immunoassay device).
- •5. Clinical diagnosis of opioid dependence syndrome (F11.2) with current physical dependence such that an antagonist medication (e.g. naloxone, naltrexone) could precipitate a withdrawal syndrome
- •6. Positive naloxone challenge test at randomization (confirming opioid use) or absence of a recorded result from a naloxone provocation test.
- •7. Acute hepatitis taken as clinical jaundice on examination and/or blood bilirubin level >normal range for local reference criteria or aspartate aminotransferase or alanine aminotransferase (>3x the upper limit of the normal range).
- •8. Hepatic insufficiency (taken as >3 times the upper limit of the normal range of aspartate aminotransferase or alanine aminotransferase)
- •9. Severe renal impairment evaluated by clinical decision
- •10. Known Icenko-Cushing syndrome or to require investigation if suspected Cushingoid features/symptoms
- •11. Systemic mycoses
- •12. Clinical history of glaucoma
- •13. Clinical history of osteoporosis
- •14. pregnancy, or positive or unclear test result from pregnancy test, or intention to try to become pregnant during the study period, or is sexually active without using a birth control method (either oral hormonal contraceptives, barrier [condom or diaphragm], or Nexplanon implant) for the duration of the trial.
- •15. Currently breast-feeding
- •16. History of hypersensitivity to opioid receptor blockers (naloxone and naltrexone
- •formulations) and other components of the formulation.
- •17. History of hypersensitivity to triamcinolone or related compounds
- •18. Currently taking oral or depot naltrexone therapy or enrolment in any form of naltrexone therapy within 90 days prior to study screening, apart from treatment given by trial team between screening and randomisation.
- •19. Current criminal justice involvement with legal proceedings (not including current probation supervision) and, in the opinion of the clinical worker, is expected to fail to complete the study protocol due to re-incarceration or relocation from the centre’s catchment area.
- •20. Current (past 30 day) suicidal planning, or recent (past six months) suicide attempt.
- •21. Active, uncontrolled severe mental illness (e.g. psychosis, bipolar I disorder, schizoaffective disorder) and/or a history or evidence of organic brain disease or dementia that would comprom
研究者
相似试验
已完成
不适用
altrexone Enhanced Addiction Treatment (NEAT)ISRCTN95809946King's College London300
招募中
1 期
ong acting naltrexone for opioid addiction: the importance of mental, physical and societal factors for sustained abstinence and recoveryEUCTR2017-004706-18-NOAkershus University Hospital150
进行中（未招募）
不适用
Extended Release Naltrexone for Treating Amphetamine Dependence in IcelandAmphetamine dependenceEUCTR2009-013647-10-ISational Institute on Drug Abuse (NIDA)
撤回
3 期
altrexone as anti-craving medication in cannabis addictsverslaving aan cannabiscannabis addictionNL-OMON35633Centrum Maliebaan (Utrecht)60
已完成
不适用
altrexone for the treatment of amphetamine dependence: a randomised placebo controlled trialAmphetamine abuse and dependenceMental and Behavioural DisordersAmphetamine dependenceISRCTN29945787Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)80